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Background: Fusidic acid (FA) (WU-FA-00) is the only commercially available antimicrobial 
from the fusidane family that has a narrow spectrum of activity against Gram-positive bacteria.
Methods: Herein, the hydrogenation derivative (WU-FA-01) of FA was prepared and both com-
pounds were examined against a panel of six bacterial strains. In addition, their anti-inflammatory 
properties were evaluated using a 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced mouse 
ear edema model.
Results: The results of the antimicrobial assay revealed that both WU-FA-00 and WU-FA-01 
displayed a high level of antimicrobial activity against Gram-positive strains. Moreover, killing 
kinetic studies were performed and the results were in accordance with the minimum inhibi-
tory concentration and minimum bactericidal concentration results. We also demonstrated that 
the topical application of WU-FA-00 and WU-FA-01 effectively decreased TPA-induced ear 
edema in a dose-dependent manner. This inhibitory effect was associated with the inhibition of 
TPA-induced upregulation of proinflammatory cytokines IL-1β, TNF-α, and COX-2. WU-FA-01 
significantly suppressed the expression levels of p65, IκB-α, and p-IκB-α in the TPA-induced 
mouse ear model. 
Conclusion: Overall, our results showed that WU-FA-00 and WU-FA-01 not only had effective 
antimicrobial activities in vitro, especially to the Gram-positive bacteria, but also possessed 
strong anti-inflammatory effects in vivo. These results provide a scientific basis for developing 
FA derivatives as antimicrobial and anti-inflammatory agents.
Keywords: fusidic acid, derivative, antimicrobial, anti-inflammatory
Introduction
Over the past few decades, the appreciation of the key role of inflammation in disease 
diagnosis, prevention, and treatment has burgeoned.1,2 Inflammation has been defined as 
a complex biological response of vascular tissues to different types of harmful stimuli,3,4 
such as damaged cells, irritants, and pathogens. Inflammation has also been linked 
to the release of proinflammatory cytokines,5,6 12-O-tetradecanoylphorbol-13-acetate 
(TPA) is a well-known inducer of inflammatory,7,8 and the signal transduction pathways 
such as MAPK, p65, and I-κB kinase (IKK) activate proinflammatory transcription 
factors including NF-κB, activator protein 1 (AP-1), and cAMP response element-
binding protein.9,10 These transcription factors are critically involved in the expression 
of various proinflammatory genes,11–14 including tumor necrosis factor-alpha (TNF-α), 
interleukin-1β (IL-1β), interleukin-6 (IL-6), and cyclooxygenase-2 (COX-2), all of 
which could be a sign of many diseases.4,15 Therefore, inflammation is a biological 
response, wherein the organism attempts to remove the injurious stimuli and initiate 
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the healing process for the tissue; thus, it could be regarded 
as a protective effect.4
Currently, steroids and nonsteroidal anti-inflammatory 
drugs are proverbially used as effective therapeutic anti-
inflammatory agents in clinical applications.4 Despite the 
widespread use of anti-inflammatory drugs, there may be 
some residual risks of inflammation and the side effects of 
their long-term oral administration,16 especially in infectious 
diseases, in which patients suffer from not only the inflam-
matory responses but also the pathogenic microorganism 
infections.17–19
Fusidic acid (FA) (WU-FA-00) (Figure 1), which has 
a steroid-like scaffold structurally and is derived from the 
fungus Fusidium coccineum, is the only marketed antibiotic 
from the fusidane family. Sodium fusidate, the sodium salt 
of FA, was primarily introduced into practice as an anti-
staphylococcal therapy in 1962.20–22 However, FA has a nar-
row spectrum of biological activity against some anaerobic 
Gram-negative organisms and most Gram-positive bacteria, 
especially the staphylococci, including the methicillin-
resistant Staphylococcus aureus (MRSA) and coagulase-
negative staphylococci.23–25 Although some antimicrobial 
activity and reasonable anti-inflammatory effects have been 
discovered,26,27 there is no in-depth study of FA and its deriva-
tives as potential anti-inflammatory agents. Therefore, the 
therapeutic efficacy of FA and its derivatives as antimicrobial 
and anti-inflammatory agents should be explored.
In the present study, the in vitro antimicrobial activities 
of FA and its hydrogenation derivative (WU-FA-01) were 
investigated against six bacterial strains, including five Gram-
positive bacterial strains and one Gram-negative bacteria 
strain. In parallel, TPA was used as an inducer to explore 
both compounds’ inhibitory activity on skin inflammation in a 
mouse ear edema model.28–30 Moreover, immunohistochemical 
analysis was introduced to reveal their inhibitory effects on 
the expression of TPA-induced TNF-α, IL-1β, and COX-2 in 
mouse ears. Furthermore, the anti-inflammatory mechanisms 
of FA and its hydrogenation derivative were also discussed to 
gain insight into their effects. Accordingly, FA is already a 
licensed antimicrobial with well-described anti-inflammatory 
properties. Its 24,25-dihydrofusidic acid derivative could be 
developed as antimicrobial with well anti-inflammatory agents.
Materials and methods
chemicals
FA was purchased from Macklin Co., Ltd. (Shanghai, China), 
with over 98% purity. TPA was ordered from Sigma-Aldrich 
Co. (St Louis, MO, USA). TPA, FA, and its derivative were 
dissolved in acetone to produce the desired concentrations 
of each compound. TNF-α and IL-1β antibodies were pur-
chased from Bioss Biotechnology Co. (Beijing, China) and 
Beyotime Biotechnology Co. (Beijing, China). The silica gel 
(200–300 mesh) used in the column chromatography was 
supplied by Inno-chem Co., Ltd. (Beijing, China). All other 
reagents and solvents were purchased from Adamas Reagent 
Ltd. (Shanghai, China) or other commercial suppliers in their 
analytically or chemically pure forms and used without purifi-
cation. All of the compounds used in this study were diluted in 
acetone or dimethyl sulfoxide (DMSO) to get a stock solution 
for further dilution to obtain the final concentration. Thin-layer 
chromatography (TLC) was performed on precoated silica gel 
F
254
 plates (0.25 mm; Merck Millipore, Billerica, MA, USA); 
the starting material and the product were detected by either 
viewing under UV light or treating with an ethanolic solu-
tion of p-anisaldehyde spray followed by heating.  Mueller 
Hinton agar (MHA) and Mueller Hinton broth (MHB) were 
purchased from Guangdong Huankai Microbial Sci. & Tech. 
Co., Ltd. (Guangdong, China). The antimicrobial activity was 
determined by using a Multimode Plate Reader (Infinite 200, 
TECAN, Guangzhou, Guangdong, China).
Preparation of WU-Fa-01
A 100 mL glassware was flamed-dried and allowed to 
cool in a desiccator before use. FA (1.0 g, 1.94 mmol) was 
Figure 1 chemical structure and conformation of fusidic acid (WU-Fa-00).
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dissolved in 50 mL of ethanol. About 5% of palladium on 
calcium carbonate (0.1 g, 0.19 mmol) was added to the 
reaction. Moreover, the reaction mixture was subjected to 
a vacuum-nitrogen purge and left to stir under a hydrogen 
atmosphere for 3 hours. TLC was eluted in the mixture 
of ethyl acetate:petroleum ether =1:2 (v:v) and stained in 
p-anisaldehyde. R
f
 value of the starting material was 0.14 and 
the product was 0.17. Then, the reaction mixture was filtered 
through a pad of Celite and washed with ethyl acetate. The 
solvent was removed under vacuum to obtain a white solid 
(yield: >98%).
Microorganisms and culture conditions
Six bacterial strains were used for the bioassays, including 
three Gram-positive species, S. aureus (ATCC 6538), S. 
aureus subsp. aureus (ATCC 29213), S. epidermidis (ATCC 
12228), Listeria monocytogenes (ATCC 19115), and Strepto-
coccus pneumoniae (ATCC 49619), and one Gram-negative 
species, Escherichia coli (CMCC 44102). All bacteria were 
maintained on MHA, and the cultures were stored at 4°C and 
subcultured every week.
agar disk diffusion method
The antimicrobial activity of WU-FA-00 and WU-FA-01 
was determined according to the standard agar disk diffu-
sion method with a slight modification.33–35 A 0.5 McFarland 
(1×107–1×108 CFU/mL) concentration of the bacterial sus-
pension was uniformly inoculated onto MHA solidified in 
120 mm Petri dishes. Once the dishes were prepared, 6 mm 
diameter discs of filter paper containing 5 µL of the examined 
compound, which had been diluted 10 times with DMSO, 
were pressed gently against the surface of the agar. Discs 
containing WU-FA-00 were used as the positive control, 
while DMSO was used as the negative control. The dishes 
were incubated in a constant temperature incubator at 37°C 
for 24 hours. The inhibition zone (IZ) diameter was measured 
by a vernier caliper. All the experiments were performed in 
triplicate.
Broth microdilution method
The minimum inhibitory concentration (MIC) and the mini-
mum bactericidal concentration (MBC) were determined by 
a microdilution method in 96-microwell plates according 
to the Clinical and Laboratory Standards Institute (CLSI), 
with a slight modification.36,37 A dilution series of the test 
compounds were obtained with DMSO as the solvent by 
twofold serial dilution. The final concentrations of the 
test compound were 1–400 µg/mL. Each well received 
5 µL of a specific concentration of the compound and 
195 µL of MHB inoculated with the test microorganism 
(1.5×105 CFU/mL); the final concentration of the test 
compound reached 0.025–10 µg/mL. WU-FA-00 and 
DMSO were treated as a positive control and a negative 
control, respectively. The microplates were incubated in 
a bacteriological oven for 24 hours at 37°C, and the drug 
susceptibility results were monitored by measuring the 
absorbance at 600 nm using a Multimode Plate Reader 
(Infinite 200). The lowest concentration without visible 
growth was defined as the MIC.
The MBCs were determined based on the MIC results:38,39 
serial sub-cultivation of a 5 µL of aliquot near the MIC in 
microtiter plates containing 195 µL of MHB per well and 
incubation for 24 hours at 37°C. The lowest concentration 
of antimicrobial agent that killed at least 99.9% of the start-
ing inoculum was defined as the MBC end point, which was 
determined as the lowest concentration with no visible growth 
by measuring the absorbance at 600 nm using a Multimode 
Plate Reader (Infinite 200). All experiments were conducted 
in triplicate.
Killing kinetic studies
The killing kinetic assay on the Gram-positive strains,36,40,41 
including S. aureus (ATCC 6538), S. aureus subsp. aureus 
(ATCC 29213), and S. epidermidis (ATCC 12228), was per-
formed against WU-FA-00 and WU-FA-01 in 96-microwell 
plates, and six different concentrations (0, 0.025, 0.1, 0.3125, 
0.625, and 1.25 µg/mL) of each compound were tested. The 
microplates were incubated for 24 hours at 37°C, and the 
growth of bacteria was monitored by measuring the absor-
bance at 600 nm using a Multimode Plate Reader (Infinite 
200) every 1 hour.
animals, diets, and treatments
Female Kunming mice (Guangdong, China) are the most 
productive and used mice in China, which are from Swiss 
mice; mice weighing approximately 22–25 g were used in 
the TPA-induced in vivo model. All animals were supplied 
by the Experimental Animal Center of Guangdong Province. 
They were maintained at 25±1°C with standard mouse chow 
diet and tap water ad libitum and were kept on a regular 
light–dark cycle with 50% relative humidity. All the animal 
experiments were performed according to the Ethical Regula-
tions on Animal Research of Southern Medical University 
(approval documents: SCXK/20130002).
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TPA-induced skin inflammation in mouse
The mice were divided into nine groups: each group con-
sisted of six mice, including a blank group, a TPA group, a 
dexamethasone group, and six groups for WU-FA-00 and 
WU-FA-01. In the mouse ear edema model, 20 µL of acetone 
vehicle was topically applied to the right ear and 20 µL of 
the treatment compounds at three different concentrations, 
which were dissolved in acetone, were used 5 minutes later 
after 20 µL of TPA (0.125 µg/mL in acetone) was previously 
applied to induce the inflammation model.42,43 Dexametha-
sone at a concentration of 2,500 µg/mL (6.37 µmol/mL) in 
acetone was used as the positive control. Then, all of the 
mice were maintained at a standard condition and sacrificed 
6 hours after TPA treatment. Two ear punches (9 mm in 
diameter) from the right and left ears were then harvested 
immediately and weighted; the left ear was used for com-
parison. All experiments were carried out in compliance 
with the relevant laws and institutional guidelines, which 
were approved by the Southern Medical University (approval 
documents: SCXK/20130002).
histological appearance of mouse ears
The right ear punches were fixed in 10% neutral buffered for-
malin, decalcified in EDTA buffer, subjected to a series pro-
gression of dehydration and embedded in paraffin. Sections 
of 9 mm were cut by using a microtome and were mounted 
on colorfrost microslides (VWR Scientific, Edmonton, AB, 
Canada). The sections were dried overnight and stained with 
H&E in accordance with the classical methods of histology. 
Images of the sections representing each treatment group 
were observed under a microscope (Olympus Corporation, 
Tokyo, Japan) to evaluate the damage of ear tissue.
scoring the expression of biomarkers
Each histological type of lesion in the TPA-induced ear model 
was scored independently by two experienced investigators who 
were not aware of the identity of the specimens (×200).42,44 The 
staining intensity was scored as follows: 0, no staining; 1+, faint; 
2+, moderate; and 3+, strong. 1+, 2+, and 3+ were recorded as 1, 
2, and 3 points, respectively. The staining extent was graded as 
follows: 0, no staining; 1+, ≤25% of positive cells; 2+, 26–50% 
of positive cells; and 3+, ≥51% of positive cells.
Immunohistochemical detection of 
TnF-α, Il-1β, cOX-2, p65, IκB-α, and 
p-IκB-α expressions
The ear punch tissues were fixed in formalin, and paraffinized 
sections of 5 µm thickness were incubated with 1.2% H
2
O
2
 in 
PBS to quench the endogenous peroxidase activity in order 
to minimize the nonspecific staining. Then, the sections were 
washed three times (5 minutes each) with 1 equal of TBST 
(0.05% Tween-20). Subsequently, the primary antibody of 
a proliferating cell nuclear antigen was diluted 100 times, 
applied to each section, and left overnight at 4°C. The sec-
tions were washed with PBS and incubated with a biotin-
conjugated horseradish peroxidase antibody (1:200) for 
1 hour at room temperature. Finally, peroxidase was detected 
using the 3,3-diaminobenzidine tetrahydrochloride reaction, 
which produced a brown label in the epidermal tissue. The 
cells that stained positive for TNF-α, IL-1β, and COX-2 were 
counted in the section of the mouse ear using the Image-Pro 
Plus (Version 6.0) software.42 The results were expressed as 
the number of stained cells. Immunohistochemical analysis of 
p65, IκB-α, and p-IκB-α was also conducted to gain insight 
into the signaling pathway of WU-FA-00 and WU-FA-01 in 
the TPA-induced mouse ear edema model.
statistical analysis
The results are expressed as the mean ± standard error (SE) 
or SD. Statistical comparisons among groups were performed 
using the Dunnett’s multiple test. Statistical significance was 
defined by a P-value of <0.05.
Results and discussion
chemistry
To obtain the hydrogenation derivative of FA, structural 
modifications (according to a previous study) were made at 
the double bond position of C-24 and C-25.31 The synthetic 
route is shown in Scheme 1. The 24,25-dihydrofusidic acid 
(WU-FA-01) was prepared by palladium-catalyzed hydroge-
nation in quantitative yielding. Its structure was confirmed 
by high-resolution mass spectrometry, CHNS-O elemental 
analyzer, 1H NMR, and 13C NMR, and it was in accordance 
with the previous research.31
antibacterial activity
The antibacterial activity of WU-FA-00 and WU-FA-01 was 
tested against six microorganisms, including reference strains 
consisting of Gram-negative bacteria and Gram-positive 
bacteria. All bacterial strains were cultured in MHA at 37°C 
overnight.
agar disk diffusion method
The results of the antimicrobial activity of WU-FA-00 and 
WU-FA-01 against six different microorganisms are summa-
rized in Table 1. Two different concentrations were examined 
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in this method. The sizes of the IZ indicated that the tested 
compounds with Gram-positive bacterial strains were larger 
than those with Gram-negative strains, and both compounds 
showed dose dependence. The IZ diameter was in the range of 
10.37±1.23–24.22±1.66 mm for Gram-positive strains. How-
ever, both WU-FA-00 and WU-FA-01 showed no inhibitory 
effect against the Gram-negative strains. Furthermore, the 
screening of the antimicrobial potential of the two compounds 
revealed that reducing the double bond to a single bond at 
positions C-24 and C-25 could retain their antimicrobial 
activities, specifically against the Gram-positive strains.
Broth microdilution method
A microtiter plate dilution method was conducted to deter-
mine the MIC and the MBC in a 96-well plate. At the end 
of the incubation period, the plates were evaluated for the 
Table 1 antibacterial activity of WU-Fa-00 and WU-Fa-01 expressed in the inhibition zone (mm)
Compound WU-FA-00 WU-FA-01
Structure
HO
H
H
HO
O
H
O
OH
O
 
HO
H
H
HO
O
H
O
OH
O
concentration (μg/ml) 25 12.5 25 12.5
Dosage (μg) 0.125 0.0625 0.125 0.0625
Bacterium Inhibition zone (mm)
Staphylococcus aureus
(aTcc 6538)
23.09±0.37 20.60±0.40 23.08±1.13 20.05±0.30
Staphylococcus aureus subsp. aureus
(aTcc 29213)
21.48±0.36 18.75±0.44 19.93±1.03 17.10±0.14
Staphylococcus epidermidis
(aTcc 12228)
24.22±1.66 20.04±0.35 22.91±0.84 17.42±0.40
Listeria monocytogenes
(aTcc 19115)
11.63±1.33 10.44±0.82 11.49±0.41 10.55±1.20
Streptococcus pneumoniae
(aTcc 49619)
8.22±0.79 7.37±1.23 9.39±0.90 7.52±1.11
Escherichia coli
(cMcc 44102)
nD nD nD nD
Note: Data are presented as mean ± standard deviation.
Abbreviation: nD, not detected.
Scheme 1 synthesis of the hydrogenation derivative of fusidic acid (WU-Fa-01).
HO
HO
H
H
H
O
O
O
24
WU-FA-00 WU-FA-01
25
OH 1) 5% palladium on calcium carbonate
Ethanol
2) H2
HO
HO
H
H
H
O
O
O
24 25
OH
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presence or absence of bacterial growth. Each sample con-
centration was tested four times against each microorganism. 
WU-FA-00, the parent compound, was employed as a positive 
control against bacterial growth. The final concentration of 
DMSO in the 96-plate well had no effect on the bacterial 
growth.
WU-FA-00 and WU-FA-01, the two tested compounds, 
were found to be active against the microorganisms studied, 
especially the Gram-positive bacteria. The MIC and MBC 
values of the two compounds were determined according 
to the results of the microdilution method (Table 2). The 
results suggested that WU-FA-01 (MIC =0.1–0.625 µg/
mL, MBC =0.2–1.25 µg/mL) showed activity similar to 
its parent compound WU-FA-00 (MIC =0.1–0.625 µg/
mL, MBC =0.3125–1.250 µg/mL) and indicated that the 
double bond at C-24 and C-25 positions in WU-FA-00 
structure has little effect on its antibacterial activity. In 
contrast, both WU-FA-00 and WU-FA-01 were more effec-
tive against Gram-positive strains of Staphylococcus than 
the Gram-negative strains, and this result is in accordance 
with the previous agar disk diffusion studies and implied 
that WU-FA-01 could be developed as an active antibacte-
rial agent.
Killing kinetic studies
The time killing studies were carried out over a period of 
24 hours; bacteria were exposed to the tested compound at 
four different concentrations, which were determined accord-
ing to their MICs. Figure 2 displays the time–kill curves of 
the tested compounds for S. aureus (ATCC 6538), S. aureus 
subsp. aureus (ATCC 29213), and Staphylococcus epider-
midis (ATCC 12228). As shown in Figure 2, the MICs of 
the tested compounds were sufficient to inhibit almost all of 
the bacterial growth but with a slight increase after 20 hours 
during this assay. Similar to the MBC results, no remarkable 
difference in the bacterial counts was found after incubation 
for 24 hours at MICs and the results confirmed that the MBCs 
were highly effective for killing bacteria. Furthermore, the 
bacterial population incubated with DMSO or with the test 
compounds, which were lower than that of their MICs, indi-
cated less inhibitory action upon all selected bacterial strains. 
Moreover, Figure 2 indicates that there is no difference in 
the observation of bacterial killing at higher concentrations 
of both compounds.
Inhibitory effects of WU-Fa-00 and WU-
Fa-01 on TPa-induced edema in a mouse 
ear model
A TPA-induced ear edema mouse model was utilized to 
evaluate the in vivo anti-inflammatory activities of WU-FA-
00 and WU-FA-01. It has been reported that TPA, which 
was normally adopted in this investigation model, is a well-
known promoter of skin inflammation. The average weight 
of the ear punches is an important indicator that reflects 
the degree of skin edema when compared with the vehicle 
control group. As shown in Figure 3, the weight of mouse 
ear punches was significantly increased to 160.90% after 
6 hours when 20 µL of TPA (0.125 µg/mL in acetone) was 
topically applied  compared to the acetone-treated control 
group. Topical application of 2,000, 4,000, and 8,000 µg/
mL of WU-FA-00 after TPA treatment modestly inhibited 
TPA-induced ear edema by 39.04, 73.46, and 83.83%, 
respectively, compared with the TPA group. However, 
2,000, 4,000, and 8,000 µg/mL of WU-FA-01 significantly 
decreased the TPA-induced ear edema by 48.16, 113.97, 
and 137.32%, respectively, in a dose-dependent manner. 
Table 2 antibacterial activities of WU-Fa-00 and WU-Fa-01 expressed in MIc and MBc (μg/ml)
Bacteria Compounds
WU-FA-00 WU-FA-01
MIC MBC MIC MBC
μg/mL μg/mL
gram-positive bacteria Staphylococcus aureus (aTcc 6538) 0.1 0.3125 0.1 0.2
Staphylococcus aureus subsp. aureus (aTcc 29213) 0.625 1.25 625 1.25
Staphylococcus epidermidis (aTcc 12228) 0.625 1.25 0.625 1.25
Listeria monocytogenes (aTcc 19115) >1.25 >1.25 >1.25 >1.25
Streptococcus pneumoniae (aTcc 49619) >1.25 >1.25 >1.25 >1.25
gram-negative bacteria Escherichia coli (cMcc 44102) nD nD nD nD
Notes: MIc (μg/ml), ie, the lowest concentration of the compound that completely inhibits the growth of bacteria. MBc (μg/ml), ie, the lowest concentration of the 
compound that completely kills the bacteria.
Abbreviations: MBc, minimum bacterial concentration; MIc, minimum inhibitory concentration; nD, not detected.
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Figure 2 Time–kill curves for the three gram-positive strains.
Notes: Staphylococcus aureus (aTcc 6538) (A and D), Staphylococcus epidermidis (aTcc 12228) (B and E), and S. aureus subsp. aureus (aTcc 29213) (C and F), exposed 
to four different concentrations of WU-Fa-00 (A–C) and WU-Fa-01 (D–F) according to their respective MIcs (n=4).
Abbreviation: MIc, minimum inhibitory concentration.
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Figure 3 Inhibition effects of WU-Fa-00 and WU-Fa-01 on TPa-induced edema in mouse ears.
Notes:  The right ears of all animals (n=6) were topically treated with 20 μl of acetone (vehicle control) or WU-Fa-00/WU-Fa-01 (2, 4, or 8 mg/ml)/Dexamethasone 
(2.5 mg/mL) in 20 µL of acetone after the application of TPA (2 mg/mL) in 20 µL of acetone. The mice were sacrificed 6 hours after the TPA treatment. Both ear punches 
(9 mm in diameter) were immediately taken, and then, they were weighted and measured. The data from each group are expressed as mean ± sD. compared to the TPa-
induced model group (n=6), *P<0.05 and **P<0.01 (Dunnett’s multiple comparison test). The minus symbols mean not present, the plus symbols mean present.
Abbreviation: TPa, 12-O-tetradecanoylphorbol-13-acetate.
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Furthermore, the compound WU-FA-01 had a similar 
effect on the positive control when it was used at a dose 
of 4,000 µg/mL (7.71 µmol/mL) with an inhibition rate of 
113.97%, whereas dexamethasone had an inhibition rate 
of 134.13% at a dose of 2,500 µg/mL (6.37 µmol/mL). 
There is no significant difference between the two fusidane 
compounds from the statistical comparison (Figure 3); all 
right ear punches were adopted as a standard to evaluate the 
increase in the average weight and thickness of ear punches. 
This result also suggested that WU-FA-01 had stronger 
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protective effects than WU-FA-00 against TPA-induced 
skin inflammation.
Inhibitory effects of WU-Fa-00 
and WU-Fa-01 on the histological 
appearance of mouse ears
To investigate the role of WU-FA-00 and WU-FA-01 in 
the histological appearance of a TPA-induced mouse ear 
model, both WU-FA-00 and WU-FA-01 were evaluated 
by transdermal application. In this model, the right ears 
of each group of mice were pretreated with 20 µL of TPA 
(0.125 µg/mL in acetone), while the controls were topically 
adopted with acetone. The treatment compounds (20 µL) at 
three different concentrations were dissolved in acetone and 
used 5 minutes later. Dexamethasone was used as a positive 
control at a concentration of 2,500 µg/mL (6.37 µmol/mL) 
in acetone, which is more comparable to the dosage of two 
tested fusidane compounds. After the ear tissues had been 
stained with H&E stain, as shown in Figure 4, the histologi-
cal appearances of the ear sections indicated that the ears 
treated with acetone alone appeared normal in the epidermal 
layer without any obvious lesion. However, the TPA alone 
group displayed significant swelling, which was consistent 
with the results of the ear thickness and the ear punch weight 
(Figure 3). Moreover, the topical application of WU-FA-00 
and WU-FA-01 could effectively suppress signs of the inflam-
matory response, such as epidermal hyperplasia and dense 
dermal leukocyte infiltration.
Inhibition of TPa-induced expression of 
TnF-α, Il-1β, and cOX-2
To gain insight into the molecular mechanisms by which 
WU-FA-00 and WU-FA-01 suppressed TPA-induced skin 
inflammation, we examined the effects of both WU-FA-00 
and WU-FA-01 on the expression levels of proinflammatory 
cytokines, including TNF-α, IL-1β, and COX-2, in mouse 
ears using immunohistochemical analysis. As shown in 
 Figure 5, the expression level of proinflammatory cytokines 
at red arrows (TNF-α, IL-1β, and COX-2) were dramatically 
elevated 6 hours after topical stimulation with TPA, which 
was apparently downregulated in a dose-dependent manner 
by treatment with WU-FA-00 and WU-FA-01. However, 
Figure 4 h&e staining for histological changes in TPa-induced mouse ears treated with an acetone control, TPa, WU-Fa-00, and WU-Fa-01 at different concentrations.
Notes: The data from each group are expressed as mean ± sD. compared to the TPa-induced model group (n=6), *P<0.05, **P<0.01 (Dunnett’s multiple comparison test). 
Magnification 200×. The arrows indicate the lesion or swelling or epidermal hyperplasia or dense dermal leukocyte infiltration of the ear tissues.
Abbreviation: TPa, 12-O-tetradecanoylphorbol-13-acetate.
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Figure 5 Effects of WU-FA-00 and WU-FA-01 treatment on proinflammatory cytokines’ levels of TNF-α (A), Il-1β (B), and cOX-2 (C) in a mouse ear model.
Notes: Mouse ears treated with acetone, TPa, WU-Fa-00, and WU-Fa-01 at different concentrations were analyzed by immunohistochemical staining. The data are shown 
as mean ± sD. compared to the TPa-induced model group (n=6), *P<0.05 and **P<0.01 (Dunnett’s multiple comparison test). Magnification 200×.
Abbreviation: TPa, 12-O-tetradecanoylphorbol-13-acetate.
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the proinflammatory cytokine levels of TNF-α, IL-1β, and 
COX-2 between the treated groups and the control group in 
the TPA-induced mouse ear model were increased 20.37-, 
31.47-, and 3.16-fold. First, 2,000, 4,000, and 8,000 µg/
mL of WU-FA-00 retarded TPA-induced overexpression of 
TNF-α by 5.1, 52.9, and 80.7%, while 2,000, 4,000, and 
8,000 µg/mL of WU-FA-01 retarded TPA-induced overex-
pression of TNF-α by 20.5, 56.5, and 82.5% relative to the 
TPA group, respectively (Figure 5A). Second, WU-FA-00 
at 2,000, 4,000, and 8,000 µg/mL greatly reduced the over-
expression of IL-1β by 36.0, 59.8, and 86.1%, while 2,000, 
4,000, and 8,000 µg/mL of WU-FA-01 greatly reduced the 
overexpression of IL-1β by 35.9, 65.6, and 86.6%, respec-
tively (Figure 5B). Third, 2,000, 4,000, and 8,000 µg/mL of 
WU-FA-00 retarded TPA-induced overexpression of COX-2 
by 8.3, 26.7, and 45.8%, while 2,000, 4,000, and 8,000 µg/
mL of WU-FA-01 retarded TPA-induced overexpression of 
COX-2 by 12.1, 31.6, and 56.6%, compared to the TPA group, 
respectively (Figure 5C). Therefore, the above results indicate 
that WU-FA-00 and WU-FA-01 could markedly suppress the 
overexpression of proinflammatory cytokines, which was in 
accordance with the previous results of ear weight and ear 
thickness (Figure 3) and histological changes (Figure 4) in 
this TPA-induced ear model.
Inhibition of TPa-induced expression of 
p65, IκB-α, and p-IκB-α
The activation of NF-κB is significant for the regula-
tion of TNF-α, IL-1β, and COX-2 overexpression in the 
TPA-induced inflammatory model. Therefore, whether 
WU-FA-00 and WU-FA-01 could affect the NF-κB sig-
naling pathway was determined by immunohistochemical 
analysis. As illustrated in Figure 6A by red arrows, the 
results revealed that p65 was markedly suppressed by the 
treatment of WU-FA-00 and WU-FA-01, in which both 
WU-FA-00 and WU-FA-01 were more active at a concentra-
tion of 8,000 µg/mL. Moreover, the results confirmed that 
the transcriptional activity was markedly upregulated in the 
TPA-induced model but was inhibited by WU-FA-00 and 
WU-FA-01 at 8,000 µg/mL.
The signaling pathway of IKK is involved in the induc-
tion of proinflammatory cytokines via the modulation 
of NF-κB. Thus, it is necessary to gain insights into the 
IκB-α/p-IκB-α pathway in this TPA-induced model. From 
the immunohistochemical analysis in Figure 6B and C at 
red arrows, the levels of IκB-α and p-IκB-α in the TPA 
group were significantly increased. However, they could 
be suppressed by WU-FA-00 and WU-FA-01 in a dose-
dependent manner, especially at a higher concentration of 
8,000 µg/mL. IκB-α deletion, however, has no effect on 
NF-κB activation by most agents. Which kinase induces 
the phosphorylation of p65 is controversial, but protein 
kinase A, casein kinase II, IKK-α, and IKK-β have been 
implicated. The phosphorylation of p65 has been shown 
to be required for the TNF-induced transcriptional activity 
of NF-κB.32 These results imply that both WU-FA-00 and 
WU-FA-01 might block the activation of NF-κB through 
interfering with p65 and IκB-α/p-IκB-α to inhibit the 
expression of the TPA-induced proinflammatory cytokines 
of TNF-α, IL-1β, and COX-2.
Conclusion
Both WU-FA-00 and WU-FA-01 not only possessed excel-
lent in vitro antimicrobial activities for Gram-positive 
Staphylococcus strains but also exhibited effective inhibition 
effects in the TPA-induced mouse ear model. Thus, both 
WU-FA-00 and WU-FA-01 could be considered as inhibitors 
of inflammation induced by bacterial infection. Moreover, 
it is possible that inflammation is frequently triggered by 
bacterial infection. The inhibitory effect of WU-FA-01 
against microorganisms and TPA-induced skin inflamma-
tion is similar to its parent compound. The inhibitory effect 
of both compounds was associated with the suppression 
of TPA-stimulated proinflammatory cytokines of TNF-α, 
IL-1β, and COX-2. This study provides a further under-
standing of the anti-inflammatory properties of WU-FA-00 
and WU-FA-01. Therefore, the results of this study implied 
that FA and the dihydro analog could be developed as di-
functional agents, which possess both antimicrobial and 
anti-inflammatory activities.
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Figure 6 Inhibitory effects of WU-Fa-00 and WU-Fa-01 on the phosphorylation of p65 (A), IκB-α (B), and p-IκB-α (C) in the TPa-induced ear model.
Notes: Mouse ears treated with acetone, TPa, WU-Fa-00, and WU-Fa-01 at different concentrations were analyzed by immunohistochemical staining. The data are shown 
as mean ± sD. compared to the TPa-induced model group (n=6), *P<0.05, **P<0.01 (Dunnett’s multiple comparison test). Magnification 200×. The arrows point to the the 
expression levels of key protein (p65 and p-IκB-α) in the pathway, using immunohistochemical analysis.
Abbreviation: TPa, 12-O-tetradecanoylphorbol-13-acetate; IOD, integral optical density.
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